Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Frank Rueckl

Dermatology Las Vegas, NV Medical Doctor

NPI 1588749857 CMS profile 116916

8861 W Sahara Ave Ste 290, Las Vegas, NV 89117

Open in the dashboard

General payments

$10,708

169 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Frank Rueckl of Las Vegas, NV is reported in the CMS Open Payments database as having received $10,708 across 169 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $137 7
2022 General $629 31
2021 General $1,695 55
2020 General $3,320 45
2019 General $4,927 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Frank Rueckl
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Frank Rueckl were reported at $0. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Frank Rueckl Dermatology median Middle half National median
2019 $4,927 $454 $129–$1,240 $163
2020 $3,320 $235 $81–$756 $114
2021 $1,695 $377 $108–$1,108 $132
2022 $629 $514 $143–$1,391 $149
2023 $137 $607 $159–$1,674 $160
2024 $0 $751 $204–$1,903 $164
2025 $0 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Allergan Inc. $7,897 31 payments
  2. AbbVie, Inc. $712 41 payments
  3. Pfizer Inc. $319 18 payments
  4. Merz North America, Inc. $295 3 payments
  5. Sun Pharmaceutical Industries Inc. $231 13 payments
  6. Regeneron Healthcare Solutions, Inc. $163 7 payments
  7. VYNE Pharmaceuticals Inc. $159 6 payments
  8. Genzyme Corporation $152 9 payments
  9. Almirall LLC $126 6 payments
  10. Amgen Inc. $119 5 payments
  11. Other $535 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $7,500 6 payments
  2. Food and Beverage $3,208 163 payments
Products named General payments · program years 2019–2023
  1. KYBELLA $2,009 2 payments
  2. BOTOX COSMETIC $1,058 9 payments
  3. BOTOX $729 10 payments
  4. SKYRIZI $356 20 payments
  5. HUMIRA $333 20 payments
  6. EUCRISA $287 16 payments
  7. DUPIXENT $163 7 payments
  8. AMZEEQ $159 6 payments
  9. RINVOQ $159 9 payments
  10. Seysara $126 6 payments
  11. Other $1,589 86 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

169 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record